Systematic Review and Meta-Analysis on Human African Trypanocide Resistance

Background Human African trypanocide resistance (HATr) is a challenge for the eradica- tion of Human African Trypansomiaisis (HAT) following the widespread emergence of increased monotherapy drug treatment failures against Trypanosoma brucei gambiense and T. b. rhodesiense that are associated wit...

Full description

Saved in:
Bibliographic Details
Main Authors: Keneth Iceland, Kasozi, Ewan Thomas, MacLeod, Susan Christina, Welburn
Format: Article
Language:English
Published: MDPI. 2023
Subjects:
Online Access:http://hdl.handle.net/20.500.12493/926
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1800403077624233984
author Keneth Iceland, Kasozi
Ewan Thomas, MacLeod
Susan Christina, Welburn
author_facet Keneth Iceland, Kasozi
Ewan Thomas, MacLeod
Susan Christina, Welburn
author_sort Keneth Iceland, Kasozi
collection KAB-DR
description Background Human African trypanocide resistance (HATr) is a challenge for the eradica- tion of Human African Trypansomiaisis (HAT) following the widespread emergence of increased monotherapy drug treatment failures against Trypanosoma brucei gambiense and T. b. rhodesiense that are associated with changes in pathogen receptors. Methods: Electronic searches of 12 databases and 3 Google search websites for human African trypanocide resistance were performed using a keyword search criterion applied to both laboratory and clinical studies. Fifty-one publications were identified and included in this study using the PRISMA checklist. Data were analyzed using RevMan and random effect sizes were computed for the statistics at the 95% confidence interval. Results: Pentamidine/melarsoprol/nifurtimox cross-resistance is associated with loss of the T. brucei adenosine transporter 1/purine 2 gene (TbAT1/P2), aquaglyceroporins (TbAQP) 2 and 3, followed by the high affinity pentamidine melarsoprol transporter (HAPT) 1. In addition, the loss of the amino acid transporter (AAT) 6 is associated with eflornithine resistance. Nifurtimox/eflornithine combination therapy resistance is associated with AAT6 and nitroreductase loss, and high resistance and parasite regrowth is responsible for treatment relapse. In clinical studies, the TbAT1 proportion of total random effects was 68% (95% CI: 38.0–91.6); I2 = 96.99% (95% CI: 94.6–98.3). Treatment failure rates were highest with melarsoprol followed by eflornithine at 41.49% (95% CI: 24.94–59.09) and 6.56% (3.06–11.25) respectively. HATr-resistant phenotypes used in most laboratory experiments demonstrated significantly higher pentamidine resistance than other trypanocides. Conclusion: The emergence of drug resistance across the spectrum of trypanocidal agents that are used to treat HAT is a major threat to the global WHO target to eliminate HAT by 2030. T. brucei strains were largely resistant to diamidines and the use of high trypanocide concentrations in clinical studies have proved fatal in humans. Studies to develop novel chemotherapeutical agents and identify alternative protein targets could help to reduce the emergence and spread of HATr.
format Article
id oai:idr.kab.ac.ug:20.500.12493-926
institution KAB-DR
language English
publishDate 2023
publisher MDPI.
record_format dspace
spelling oai:idr.kab.ac.ug:20.500.12493-9262024-01-17T04:48:12Z Systematic Review and Meta-Analysis on Human African Trypanocide Resistance Keneth Iceland, Kasozi Ewan Thomas, MacLeod Susan Christina, Welburn Human African trypanosomiasis Trypanosomes Drug resistance Pentamidines Nifurtimox/eflornithine combination therapy; Exinidazole; NECT TbAT Amino-aquapurine trans- porters Amino acid transporters Trypanosoma brucei rhodesiense Trypanosoma brucei gambiense Neglected tropical diseases Background Human African trypanocide resistance (HATr) is a challenge for the eradica- tion of Human African Trypansomiaisis (HAT) following the widespread emergence of increased monotherapy drug treatment failures against Trypanosoma brucei gambiense and T. b. rhodesiense that are associated with changes in pathogen receptors. Methods: Electronic searches of 12 databases and 3 Google search websites for human African trypanocide resistance were performed using a keyword search criterion applied to both laboratory and clinical studies. Fifty-one publications were identified and included in this study using the PRISMA checklist. Data were analyzed using RevMan and random effect sizes were computed for the statistics at the 95% confidence interval. Results: Pentamidine/melarsoprol/nifurtimox cross-resistance is associated with loss of the T. brucei adenosine transporter 1/purine 2 gene (TbAT1/P2), aquaglyceroporins (TbAQP) 2 and 3, followed by the high affinity pentamidine melarsoprol transporter (HAPT) 1. In addition, the loss of the amino acid transporter (AAT) 6 is associated with eflornithine resistance. Nifurtimox/eflornithine combination therapy resistance is associated with AAT6 and nitroreductase loss, and high resistance and parasite regrowth is responsible for treatment relapse. In clinical studies, the TbAT1 proportion of total random effects was 68% (95% CI: 38.0–91.6); I2 = 96.99% (95% CI: 94.6–98.3). Treatment failure rates were highest with melarsoprol followed by eflornithine at 41.49% (95% CI: 24.94–59.09) and 6.56% (3.06–11.25) respectively. HATr-resistant phenotypes used in most laboratory experiments demonstrated significantly higher pentamidine resistance than other trypanocides. Conclusion: The emergence of drug resistance across the spectrum of trypanocidal agents that are used to treat HAT is a major threat to the global WHO target to eliminate HAT by 2030. T. brucei strains were largely resistant to diamidines and the use of high trypanocide concentrations in clinical studies have proved fatal in humans. Studies to develop novel chemotherapeutical agents and identify alternative protein targets could help to reduce the emergence and spread of HATr. Kabale University 2023-02-02T05:16:28Z 2023-02-02T05:16:28Z 2022-09-25 Article Kasozi, K.I.; MacLeod, E.T.; Welburn, S.C. Systematic Review and Meta-Analysis on Human African Trypanocide Resistance. Pathogens 2022, 11, 1100. https://doi.org/ 10.3390/pathogens11101100 http://hdl.handle.net/20.500.12493/926 en Attribution-NonCommercial-NoDerivs 3.0 United States http://creativecommons.org/licenses/by-nc-nd/3.0/us/ application/pdf MDPI.
spellingShingle Human African trypanosomiasis
Trypanosomes
Drug resistance
Pentamidines
Nifurtimox/eflornithine combination therapy;
Exinidazole;
NECT
TbAT
Amino-aquapurine trans- porters
Amino acid transporters
Trypanosoma brucei rhodesiense
Trypanosoma brucei gambiense
Neglected tropical diseases
Keneth Iceland, Kasozi
Ewan Thomas, MacLeod
Susan Christina, Welburn
Systematic Review and Meta-Analysis on Human African Trypanocide Resistance
title Systematic Review and Meta-Analysis on Human African Trypanocide Resistance
title_full Systematic Review and Meta-Analysis on Human African Trypanocide Resistance
title_fullStr Systematic Review and Meta-Analysis on Human African Trypanocide Resistance
title_full_unstemmed Systematic Review and Meta-Analysis on Human African Trypanocide Resistance
title_short Systematic Review and Meta-Analysis on Human African Trypanocide Resistance
title_sort systematic review and meta analysis on human african trypanocide resistance
topic Human African trypanosomiasis
Trypanosomes
Drug resistance
Pentamidines
Nifurtimox/eflornithine combination therapy;
Exinidazole;
NECT
TbAT
Amino-aquapurine trans- porters
Amino acid transporters
Trypanosoma brucei rhodesiense
Trypanosoma brucei gambiense
Neglected tropical diseases
url http://hdl.handle.net/20.500.12493/926
work_keys_str_mv AT kenethicelandkasozi systematicreviewandmetaanalysisonhumanafricantrypanocideresistance
AT ewanthomasmacleod systematicreviewandmetaanalysisonhumanafricantrypanocideresistance
AT susanchristinawelburn systematicreviewandmetaanalysisonhumanafricantrypanocideresistance